Currently, synthetic inhibitors of CCL2, Bindarit(Bnd) (80) and Carlumab(CNTO 888) (81), as well as CCR2 antagonists RS-50439 and MLN1202, have been developed for targeted disruption of CCL2/CCR2 signaling to intervene in the progression of various tumor types (82–85). This evidence concerns the gene CCR2 and neoplasm.